rct
    2013

    Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease

    Nunes MA, Viel TA, Buck HS

    Published in Current Alzheimer Research

    Key Findings

    Microdose lithium (300 micrograms/day) was associated with stable MMSE scores over 15 months while controls declined.

    Conclusions

    Hypothesis-generating signal for very low-dose lithium in Alzheimer disease.

    Limitations

    Very small sample, single centre, not replicated.

    Supplements Studied

    Microdose lithium was associated with stable MMSE scores over 15 months while the control group declined.

    Outcomes Measured

    Cognitive Function

    MMSE scores remained stable over 15 months with microdose lithium while controls declined.

    Related Health Concerns

    Alzheimer's Disease

    Study Details

    Year:2013
    Sample Size:113
    Duration:64 weeks
    Quality Score:5/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.